Impact of SOFT/TEXT in Premenopausal Breast Cancer

Video

This video reviews the impact of the SOFT/TEXT trials for the treatment of patients with premenopausal breast cancer, and ways to best use the results.

In this video, Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre in Melbourne, reviews the impact of the SOFT/TEXT trials for the treatment of premenopausal breast cancer patients, and ways to best use the results.

Francis gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Recent Videos
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
1 expert in this video
1 expert in this video
1 expert in this video
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Related Content
Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

Elucidating the Clinical Landscape for Rare Lymphoma Treatment

Roman Fabbricatore
April 17th 2025
Article

Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

Ariana Pelosci
April 17th 2025
Article

After the recent approval of 177Lu in PSMA+/mCPRCP prior to chemotherapy, Steven Finkelstein, MD, DABR, FACRO, highlights the importance of this milestone.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Bria-IMT Enhances Survival vs Sacituzumab Govitecan in HR+ Breast Cancer

Roman Fabbricatore
April 17th 2025
Article

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Three Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy

Three Things You Should Know About Advances in Gastroesophageal Adenocarcinoma Therapy

ONCOLOGY Staff
April 17th 2025
Article

Immunotherapy combinations and targeted therapy options may help bridge clinical gaps in early-stage, locally advanced, and metastatic gastroesophageal adenocarcinomas.